Novartis (NVS) EBITDA (2006 - 2026)
Novartis (NVS) EBITDA from Mar 31, 2006 to Mar 31, 2026. The TTM Novartis (NVS) EBITDA is $22B. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual EBITDA
Quarterly EBITDA
Novartis (NVS) EBITDA CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | +2.37% |
| 3 Years TTM | +11.29% |
| 5 Years TTM | +5.31% |
| 10 Years TTM | +4.79% |
| All Time TTM | +4.00% |
Annual EBITDA change of Novartis (NVS)
| Year | EBITDA | Change |
|---|---|---|
| 2026 | $5.41B | -76.47% |
| 2025 | $23B | +10.97% |
| 2024 | $21B | +13.48% |
| 2023 | $18B | +24.34% |
| 2022 | $15B | -52.51% |
| 2021 | $31B | +79.62% |
| 2020 | $17B | +10.21% |
| 2019 | $16B | -22.84% |
| 2018 | $20B | +38.73% |
| 2017 | $15B | +0.14% |
| 2016 | $15B | +2.15% |
| 2015 | $14B | -19.24% |
| 2014 | $18B | +11.09% |
| 2013 | $16B | -3.09% |
| 2012 | $16B | -4.05% |
| 2011 | $17B | +8.10% |
| 2010 | $16B | +23.79% |
| 2009 | $13B | +2.53% |
| 2008 | $12B | +17.74% |
| 2007 | $11B | +3.92% |
| 2006 | $10B | N/A |
Comparison Novartis (NVS) five years EBITDA CAGR with competitors
Novartis (NVS) five years EBITDA CAGR is 5.31%.
| Ticker | Name | five years EBITDA CAGR | Upside |
|---|---|---|---|
| LLY | Lilly(Eli) & Company | 30.95% | +482.40% |
| AZN | Astrazeneca plc | 18.02% | +239.14% |
| GILD | Gilead Sciences Inc | 17.19% | +223.50% |
| BMY | Bristol-Myers Squibb Company | 13.61% | +156.04% |
| MRK | Merck & Co Inc | 10.17% | +91.27% |
| JNJ | Johnson & Johnson | 6.13% | +15.42% |
| ABBV | Abbvie Inc | 4.99% | -6.06% |
| AMGN | AMGEN Inc | 4.42% | -16.88% |
| GRFS | Grifols SA | 2.72% | -48.74% |
| GSK | GSK Plc | 1.17% | -78.02% |